Formation of anti-infectious and post-vaccination anti-SARS-CoV-2 humoral immunity in medical workers of the perinatal center
- Authors: Chistyakova G.N.1, Malgina G.B.1, Ustyuzhanin A.V.1, Remizova I.I.1
-
Affiliations:
- Ural Research Institute for the Protection of Maternity and Infancy
- Issue: Vol 12, No 4 (2022)
- Pages: 688-700
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/119068
- DOI: https://doi.org/10.15789/2220-7619-FOA-1856
- ID: 119068
Cite item
Full Text
Abstract
In the context of the global spread of the new coronavirus infection, studies aimed at investigating formation of anti-infectious and post-vaccination immunity are of special importance, which is necessary to prevent and reduce morbidity and mortality due to SARS-CoV-2 infection. Purpose: to assess anti-infectious immunity against SARS-CoV-2 in various forms of the disease and development of post-vaccination humoral reactions in medical workers of the perinatal center.
Materials and methods. A study of blood serum was carried out to assess SARS-CoV-2-specific IgM and IgG antibodies in 119 medical workers recovered after COVID-19, divided into groups based on the disease severity (mild, moderate and asymptomatic), as well as in 62 vaccinated employees, divided into groups according to age. Semi-quantitative measurement of virus-specific antibodies was carried out by ELISA with test systems “SARS-CoV-2-IgG-ELISA-BEST” and “SARS-CoV-2-IgM-ELISA-BEST”. Statistical processing of the research results was carried out using Microsoft Excel 2010 and Statistica 6. Quantitative characteristics were presented as median (ME), lower and upper quartiles (LQ1-UQ3); qualitative parameters — as absolute value and relative number (%). Difference between groups was analyzed by using the χ2 test (qualitative) and the Mann–Whitney U-test (quantitative).
Results. The results of the study showed that the majority of employees with a moderate-severe form of SARS-CoV-2 had a high level of IgG (PR — a positivity rate of more than 9.0 arbitrary units) 9 months after the disease compared to those who suffered from mild or asymptomatic (83.3% versus 25.8% and 13.3%, p < 0.017) infection. The duration of IgG circulation after former illness had no relation to its severity and patient age. The effectiveness of the primary vaccination “Sputnik V” and revaccination with “Sputnik Light” and “KoviVak” was 100% after inoculating the vaccine second component. The lowest level of antibodies after the first vaccination is recorded in persons over 60 years old (1.48 (1.12–3.25 versus PR = 8.48 (5.78–10.11) and 9.27 (5.84–10.31) arbitrary units, p < 0.017)), in comparison with young and middle-age subjects. The speed SARS-CoV-2 elimination of IgG at 6, 9 or more months after vaccination depends on relevant initial peak antibody concentration. Subjects who were initially vaccinated with the KoviVac vaccine, IgG was not detected 2 months after vaccination. The protective effect of “Sputnik V”, “Sputnik Light”, “KoviVac” after re-infection with SARS-CoV-2 averages 71.2%.
Conclusion. Thus, the results obtained on assessing anti-infectious and post-vaccination immunity against SARS-CoV-2 emphasize the need for further studies on a larger patient cohort, especially in those with asymptomatic infection as well as the elderly subjects.
Full Text
##article.viewOnOriginalSite##About the authors
G. N. Chistyakova
Ural Research Institute for the Protection of Maternity and Infancy
Email: chistyakovagn@niiomm.ru
ORCID iD: 0000-0002-0852-6766
PhD, MD (Medicine), Professor, Head of the Department of Immunology, Microbiology, Pathomorphology and Cytodiagnostics
Russian Federation, YekaterinburgG. B. Malgina
Ural Research Institute for the Protection of Maternity and Infancy
Email: galinamalgina@mail.ru
ORCID iD: 0000-0002-5500-6296
PhD, MD (Medicine), Associate Professor, Director
Russian Federation, YekaterinburgA. V. Ustyuzhanin
Ural Research Institute for the Protection of Maternity and Infancy
Email: ust103@yandex.ru
ORCID iD: 0000-0001-8521-7652
PhD (Medicine), Senior Researcher, Department of Immunology, Microbiology, Pathomorphology and Cytodiagnostics
Russian Federation, YekaterinburgI. I. Remizova
Ural Research Institute for the Protection of Maternity and Infancy
Author for correspondence.
Email: RemizovaII@yandex.ru
ORCID iD: 0000-0002-4238-4642
PhD (Biology), Senior Researcher, Department of Immunology, Microbiology, Pathomorphology and Cytodiagnostics
Russian Federation, 1, Repina str., Ekaterinburg, 620089References
- Агафонова Е.В., Куликов С.Н., Решетникова И.Д., Тюрин Ю.А., Гилязутдинова Г.Ф., Лопушов Д.В., Шайхразиева Н.Д., Исаева Г.Ш., Зиатдинов В.Б. Результаты исследования серопревалентности к SARS-CoV-2 у медицинских работников: возрастные и профессиональные аспекты // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 2. С. 49–57. [Agafonova E.V., Kulikov S.N., Reshetnikova I.D., Tyurin Yu.A., Gilyazutdinova G.F., Lopushov D.V., Shaуkhrazieva N.D., Isaeva G.S., Ziatdinov V.B. Seroprevalence study results to SARS-CoV-2 in healthcare workers: age and professional aspects. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2021, vol. 20, no. 2, pp. 49–57. (In Russ.)] doi: 10.31631/2073-3046-2021-20-2-49-57
- Алексанин С.С., Алхутова Н.А., Ковязина Н.А., Рыбников В.Ю. Динамика уровня антител класса G к SARS-CoV-2 после перенесенной новой коронавирусной инфекции COVID-19 // Медицинский алфавит. 2021. Т. 1, № 30. С. 7–11. [Aleksanin S.S., Alkhutova N.A., Kovyazina N.A., Rybnikov V.Yu. Dynamics of level of class G antibodies to SARS-CoV-2 after new coronavirus infection COVID-19. Meditsinskii alfavit = Medical Alphabet, 2021, vol. 1, no. 30, pp. 7–11. (In Russ.)] doi: 10.33667/2078-5631-2021-30-7-11
- Алхутова Н.А., Ковязина Н.А., Бардышева Н.А., Калинина Н.М., Алексанин С.С. Определение антител класса G к SARS-CoV-2 после применения вакцины «Гам-КОВИД-Вак» или «Спутник V» НИЦЭМ имени Н.Ф. Гамалеи // Медицинский алфавит. 2021. № 13. С. 36–40. [Alkhutova N.A., Kovyazina N.A., Bardysheva N.A., Kalinin N.M., Alexanin S.S. Determination of class G antibodies to SARS-CoV-2 after application of ‘GamCOVID-Vac’ or ‘Sputnik V’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya. Meditsinskii alfavit = Medical Alphabet, 2021, no. 13, pp. 36–40. (In Russ.)] doi: 10.33667/2078-5631-2021-13-36-40
- Амвросьева Т.В., Бельская И.В., Богуш З.Ф., Поклонская Н.В., Колтунова Ю.Б., Казинец О.Н. Характеристики и особенности формирования гуморального иммунитета после иммунизации вакцинами «Спутник V» и Vero Cell // Известия Национальной академии наук Беларуси. Серия медицинских наук. 2021. Т. 18, № 4. С. 456–465. [Amvrosieva T.V., Belskaya I.V., Bohush Z.F., Paklonskaya N.V., Kaltunova Yu.B., Kazinetz O.N. Characteristics and features of the formation of humoral immunity after immunization with Sputnik V and Vero Cell vaccines. Izvestiya Natsional’noi akademii nauk Belarusi. Seriya meditsinskikh nauk = Proceedings of the National Academy of Sciences of Belarus, Medical series, 2021, vol. 18, no. 4, pp. 456–465. (In Russ.)] doi: 10.29235/1814-6023-2021-18-4-456-465
- Блох А.И., Панюшкина И.И., Пахтусова П.О., Сергеева И.В., Левахина Л.И., Бурашникова И.П., Анпилова Н.Г., Пеньевская Н.А., Пасечник О.А., Рудаков Н.В. Оценка уровня сероконверсии к SARS-CoV-2 у персонала медико-санитарной части // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 5. С. 32–38. [Blokh A.I., Panyushkina I.I., Pakhtusova P.O., Sergeeva I.V., Levahina L.I., Burashnikova I.P., Anpilova N.G., Penyevskaya N.A., Pasechnik O.A., Rudakov N.V. Assessment of Seroconversion to SARS-CoV-2 in Health Care Unitunit Personnel. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2021, vol. 20, no. 5, pp. 32–38. (In Russ.)] doi: 10.31631/2073-3046-2021-20-5-32-38
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 13 (14.10.2021). [Interim guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13 (10/14/2021). (In Russ.)] URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf
- Драпкина О.М., Бернс С.А., Горшков А.Ю., Шишкова В.Н., Рыжакова Л.Н., Литинская О.А., Иванова А.А., Веретенникова А.В., Башняк В.С., Татаревич Е.Ю. Отдаленная динамика уровня специфических IgG-антител к S-белку коронавируса SARS-CoV-2 у вакцинированных лиц // Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 8. С. 23–28. [Drapkina O.M., Burns S.A., Gorshkov A.Yu., Shishkova V.N., Ryzhakova L.N., Litinskaya O.A., Ivanova A.A., Veretennikova A.V., Bashnyak V.S., Tatarevich E.Yu. Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention, 2021, vol. 20, no. 8, pp. 23–28. (In Russ.)] doi: 10.15829/1728-8800-2021-3124
- Кузьменко С.А., Ликстанов М.И., Ошлыкова А.М., Казакова О.С., Горяинова Т.Н., Мозес В.Г., Елгина С.И., Рудаева Е.В. Эпидемиологические особенности заболеваемости и течения новой коронавирусной инфекции COVID-19 у медицинских работников (на основе анализа данных пациентов, пролеченных в перепрофилированном инфекционном госпитале) // Медицина в Кузбассе. 2020. № 4. С. 21–24. [Kuzmenko S.A., Likstanov M.I., Oshlykova A.M., Kazakova O.S., Goryainova T.N., Mozes V.G., Elgina S.I., Rudaeva E.V. Epidemiological features of the incidence and course of the new coronavirus infection COVID-19 in medical workers (based on the analysis of data from patients treated in a re-profiled infectious diseases hospital). Meditsina v Kuzbasse = Medicine in Kuzbass, 2020, no. 4, pp. 21–24. (In Russ.)] doi: 10.24411/2687-0053-2020-100359
- Платонова Т.А., Голубкова А.А., Карбовничая Е.А., Смирнова С.С. Особенности формирования гуморального иммунитета у лиц с различными клиническими проявлениями COVID-19. // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 1. С. 20–25. [Platonova T.A., Golubkova A.A., Karbovnichaya E.A., Smirnova S.S. Features of the formation of humoral immunity in individuals with various clinical manifestations of COVID-19. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2021, vol. 20, no. 1, pp. 20–25. (In Russ.)] doi: 10.31631/2073-3046-2021-20-1-20-25
- Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Андреева Е.Е., Комбарова С.Ю., Алешкин А.В., Кобзаева Ю.В., Игнатова И.Н., Осадчая М.Н., Назаренко Е.В., Антипова Л.Н., Новикова Л.И., Бочкарева С.С., Басов А.А., Затевалов А.М., Лиханская Е.И., Мизаева Т.Э., Воробьев А.М., Галицкий А.А., Митрохин С.Д., Шкода А.С. Серопревалентность к вирусу SARS-CoV-2 среди медицинских работников г. Москвы в апреле-декабре 2020 года // Инфекционные болезни. 2021. Т. 19, № 1. С. 5–13. [Popova A.Yu., Ezhlova E.B., Melnikova A.A., Andreeva E.E., Kombarova S.Yu., Aleshkin A.V., Kobzaeva Yu.V., Ignatova I.N., Osadchaya M.N., Nazarenko E.V., Antipova L.N., Novikova L.I., Bochkareva S.S., Basov A.A., Zatevalov A.M., Likhanskaya E.I., Mizaeva T. E., Vorobyov A.M., Galitsky A.A., Mitrokhin S.D., Skoda A.S. Seroprevalence to anti- SARS-CoV-2 antibodies among healthcare professionals in Moscow in April-December 2020. Infektsionnye bolezni = Infectious Diseases, 2021, vol. 19, no. 1, pp. 5–13. (In Russ.)] doi: 10.31631/2073-3046-2021-20-1-20-25
- Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Смионов В.С., Лялина Л.В., Козловских Д.Н., Лучинина С.В., Романов С.В., Валеуллина Н.Н., Диконская О.В., Чиркова Г.Г., Малых О.Л., Пономарева А.В., Чистякова И.В., Килячина А.С., Юровских А.И., Котова А.А., Тотолян А.А. Особенности серопревалентности к SARS-CoV-2 населения Среднего и Южного Урала в начальный период пандемии COVID-19 // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 3. С. 8–18. [Popova A.Yu., Ezhlova E.B., Melnikova A.A., Smirnov V.S., Lyalina L.V., Kozlovskikh D.N., Luchinina S.V., Romanov S.V., Valeullina N.N., Dikonskaya O.V., Chirkova G.G., Malykh O.L., Ponomareva A.V., Chistyakova I.V., Kilyachina A.S., Yurovskikh A.I., Kotova A.A., Totolian A.A. Peculiarities of seroprovalence to SARS-CoV-2 in the population of the Middle and Southern Urals in the early period of the COVID-19 pandemic. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention, 2021, vol. 20, no. 3, pp. 8–18. (In Russ.)] doi: 10.31631/2073-3046-2021-20-3-8-18
- Решетникова И.Д., Тюрин Ю.А., Агафонова Е.В., Куликов С.Н., Гилязутдинова Г.Ф., Лопушов Д.В., Шайхразиева Н.Д., Исаева Г.Ш., Зиатдинов В.Б. Изучение особенностей гуморального иммунного ответа к новой коронавирусной инфекции COVID-19 среди медицинских работников // Инфекция и иммунитет. 2021. Т. 11, № 8. С. 934–942. [Reshetnikova I.D., Tyurin Yu.A., Agafonova E.V., Kulikov S.N., Gilyazutdinova G.F., Lopushov D.V., Shaуkhrazieva N.D., Isaeva G.Sh., Ziatdinov V.B. Study of features of humoral immune response to the new coronavirus infection COVID-19 among healthcare workers. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2021, vol. 11, no. 5, pp. 934–942. (In Russ.)] doi: 10.15789/2220-7619-SOT-1587
- Amjadi M.F., O’Connell S.E., Armbrust T., Mergaert A.M., Narpala S.R., Halfmann P.J., Bashar S.J., Glover C.R., Heffron A.S., Taylor A., Flach B., O’Connor D.H., Kawaoka Y., McDermott A.B., Sethi A.K., Shelef M.A. Specific COVID-19 symptoms correlate with high antibody levels against SARS-CoV-2. Immunohorizons, 2021, vol. 5, no. 6, pp. 466–476. doi: 10.4049/immunohorizons.2100022
- Bartleson J.M., Radenkovic D., Covarrubias A.J., Furman D., Winer D.A., Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. Nature Aging., 2021, vol. 1, рр. 769–782. doi: 10.1038/s43587-021-00114-7
- Bouwman M., van Osch F., Crijns F., Trienekens T., Mehagnoul-Schipper J., van den Bergh J.P., de Vries J. SARS-CoV-2 seroprevalence in healthcare workers of a teaching hospital in a highly endemic region in the Netherlands after the first wave: a cross-sectional study. BMJ, 2021, vol. 11, no. 10: e051573. doi: 10.1136/bmjopen-2021-051573
- Castro Dopico X., Ols S., Loré K., Karlsson Hedestam G.B. Immunity to SARS-CoV-2 induced by infection or vaccination. J. Intern. Med., 2022, vol. 291, no. 1, pp. 32–50. doi: 10.1111/joim.13372
- Feng C., Shi J., Fan Q., Wang Y., Huang H., Chen F., Tang G., Li Y., Li P., Li J., Cui J., Guo L., Chen S., Jiang M., Feng L., Chen L., Lei C., Ke C., Deng X., Hu F., Tang X., Li F. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nat. Commun., 2021, vol. 12, no. 1: 4984. doi: 10.1038/s41467-021-25312-0
- Kim H.J., Yun H.J., Kim J., Kym S., Choi Q. Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: a prospective longitudinal study. Vaccine, 2022, vol. 40, iss. 3, рр. 437–443. doi: doi: 10.1016/j.vaccine.2021.12.012
- Kirkcaldy R.D., King B.A., Brooks J.T. COVID-19 and post-infectious immunity: limited evidence, many unresolved questions. JAMA, 2020, vol. 323, no. 22, pp. 2245–2246. doi: 10.1001/jama.2020.7869
- Lahner E., Dilaghi E., Prestigiacomo C., Alessio G., Marcellini L., Simmaco M., Santino I., Orsi G.B., Anibaldi P., Marcolongo A., Annibale B., Napoli C. Prevalence of SARS-CoV-2 infection in health workers (HWs) and diagnostic test performance: the experience of a teaching hospital in Central Italy. Int. J. Environ. Res. Public Health., 2020, vol. 17, no. 12: 4417. doi: 10.3390/ijerph17124417
- Lin Y., Zhao Z., Zheng J., Liu J., Huang A. Realization of humoral immunity against SARS-CoV-2 infections. Fundamental Research, 2021, vol. 1, iss. 2, pp. 186–188. doi: 10.1016/j.fmre.2021.01.008
- Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, vol. 397, no. 10275, pp. 671–681. doi: 10.1016/S0140-6736(21)00234-8
- Löfström E., Eringfält A., Kötz A., Wickbom F., Tham J., Lingman M., Nygren J.M., Undén J. Dynamics of IgG-avidity and antibody levels after COVID-19. J. Clin. Virol., 2021, no. 144: 104986. doi: 10.1016/j.jcv.2021.104986
- Lumley S.F., Wei J., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., Peck L.J., Ritter T.G., de Toledo Z., Cornall R.J., Jones E.Y., Stuart D.I., Screaton G., Ebner D., Hoosdally S., Crook D.W., Conlon C.P., Pouwels K.B., Walker A.S., Peto T.E.A., Walker T.M., Jeffery K., Eyre D.W. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin. Infect. Dis., 2021, vol. 73, no. 3, pp. e699–e709. doi: 10.1093/cid/ciab004
- Malfertheiner S.F., Brandstetter S., Roth S., Harner S., Buntrock-Döpke H., Toncheva A.A., Borchers N., Gruber R., Ambrosch A., Kabesch M., Häusler S. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: a prospective longitudinal study. J. Clin. Virol., 2020, vol. 130: 104575. doi: 10.1016/j.jcv.2020.104575
- Marot S., Malet I., Leducq V., Zafilaza K., Sterlin D., Planas D., Gothland A., Jary A., Dorgham K., Bruel T., Burrel S., Boutolleau D., Schwartz O., Gorochov G., Calvez V., Marcelin A.G. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat. Commun., 2021, vol. 12: 844. doi: 10.1038/s41467-021-21111-9
- Meylan S., Dafni U., Lamoth F., Tsourti Z., Lobritz M.A., Regina J., Bressin P., Senn L., Grandbastien B., Andre C., Fenwick C., D’Acremont V., Croxatto A., Guilleret I., Greub G., Manuel O., Calandra T., Pantaleo G., Lazor-Blanchet C. SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, vol. 11, no. 7: e049232. doi: 10.1136/bmjopen-2021-049232
- Mukwege D., Byabene A.K., Akonkwa E.M., Dahma H., Dauby N., Cikwanine Buhendwa J.P., Le Coadou A., Montesinos I., Bruyneel M., Cadière G.B., Vandenberg O., Van Laethem Y. High SARS-CoV-2 seroprevalence in healthcare workers in Bukavu, Eastern Democratic Republic of Congo. Am. J. Trop. Med. Hyg., 2021, vol. 104, no. 4, pp. 1526–1530. doi: 10.4269/ajtmh.20-1526
- Nag D.S., Chaudhry R., Mishra M., Rai S., Gupta M. A prospective study on rapidly declining SARS-CoV-2 IgG antibodies within one to three months of testing IgG positive: can it lead to potential reinfections? Cureus, 2020, vol. 12, no. 12: e11845. doi: 10.7759/cureus.11845
- Poletti P., Tirani M., Sereda D., Guzzetta G., Trentini F., Marziano V., Toso C., Piatti A., Piccarreta R., Melegaro A., Andreassi A., Gramegna M., Ajelli M., Merler S. Seroprevalence and risk factors associated with SARS-CoV-2 infection among healthcare workers during the early COVID-19 pandemic in Italy. JAMA, 2021, vol. 4, no. 7: e2115699. doi: 10.1001/jamanetworkopen.2021.1569
- Rodriguez de Limia Ramirez K., Ruiz-Robledillo N., Duro-Torrijos J.L., Garcia-Roman V., Albaladejo-Blasquez N., Ferrer-Cascales R. Prevalence of SARS-CoV-2 infection among healthcare workers in two health departments of the Valencian Community in Spain. Int. J. Environ. Res. Public Health, 2021, vol. 19, no. 1: 66. doi: 10.3390/ijerph19010066
- Rose R., Neumann F., Grobe O., Lorentz T., Fickenscher H., Krumbholz A. Humoral immune response after different SARS-CoV-2 vaccination regimens. BMC Med., 2022, vol. 20, no. 31. doi: 10.1186/s12916-021-02231-x
- Sabetian G., Moghadami M., Hashemizadeh Fard Haghighi L., Shahriarirad R., Fallahi M.J., Asmarian N., Moeini Y.S. COVID-19 infection among healthcare workers: a cross-sectional study in southwest Iran. Virol J., 2021, vol. 18, no. 1: 58. doi: 10.1186/s12985-021-01532-0
- Sahu A.K., Amrithanand V.T., Mathew R., Aggarwal P., Nayer J., Bhoi S. COVID-19 in health care workers — a systematic review and meta-analysis. Am. J. Emerg. Med., 2020, vol. 38, no. 9, pp. 1727–1731. doi: 10.1016/j.ajem.2020.05.113
- Sheikh A., McMenamin J., Taylor B., Robertson S., Public Health Scotland and EAVE II staff. SARS-CoV-2 Delta VOC in Scotland: demographics, hospitalization risk and vaccine effectiveness. Lancet, 2021, vol. 397, no. 10293, pp. 2461–2462. doi: 10.1016/SO140-6736(21)01358-1
- Tretyn A., Szczepanek J., Skorupa M., Jarkiewicz-Tretyn J., Sandomierz D., Dejewska J., Ciechanowska K., Jarkiewicz-Tretyn A., Koper W., Pałgan K. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells, 2021, vol. 10, no. 8: 1952. doi: 10.3390/cells10081952
- Wei J., Matthews P.C., Stoesser N., Maddox T., Lorenzi L., Studley R., Bell J.I., Newton J.N., Farrar J., Diamond I., Rourke E., Howarth A., Marsden B.D., Hoosdally S., Jones E.Y., Stuart D.I., Crook D.W., Peto T.E.A., Pouwels K.B., Walker A.S., Eyre D.W.; COVID-19 Infection Survey team. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. Nat. Commun., 2021, vol, 12, no. 1: 6250. doi: 10.1038/s41467-021-26479-2
Supplementary files
